Tuesday, August 4, 2020
News
NEWS HOME
»
PRESS RELEASES

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
  SocialTwist Tell-a-Friend  
   


Date: 08-07-2020 9:30AM
Source: Boehringer Ingelheim
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany & WAEDENSWIL, Switzerland

Business Wire India

  • The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA)
  • Numab’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion

Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at novel therapies for difficult-to-treat lung and gastrointestinal (GI) cancers and patients with geographic atrophy (GA), a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. The collaboration brings together Boehringer Ingelheim’s leading expertise in the research and development of life changing breakthrough therapies with Numab’s multi-specific antibody platform.

Lung and GI cancers and retinal diseases are key focus areas of Boehringer Ingelheim’s research and development program. In oncology the company has built a broad and diverse pipeline, combining cancer immunology and cancer cell directed approaches. The novel T-cell engager to be developed with Numab adds to Boehringer Ingelheim’s growing cancer immunology portfolio and supports the strategy to take cancer on by targeting ‘cold’ tumors with synergistic combination approaches. In retinal diseases Boehringer Ingelheim is pursuing a holistic approach leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. The new GA program with Numab further broadens the company’s comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.

“We are thrilled to work with the excellent team at Numab to advance our portfolio assets. Numab’s technology platform fits well with our internal antibody discovery and engineering capabilities and will enhance our efforts to deliver transformative antibody-based therapeutics to patients,” said Paige Mahaney, SVP and US Discovery Research Site Head at Boehringer Ingelheim.

“We are looking forward to working with Boehringer Ingelheim, a global leader in pharmaceutical R&D with profound expertise across a broad spectrum of therapeutic areas, further validating our technology platform. This addition to our growing roster of partnerships represents another key milestone in our business development efforts,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab Therapeutics. “The upfront payment and near-term milestones attached to this alliance will further strengthen Numab’s ability to accelerate the development of key proprietary assets.”

Under the terms of the alliance, the partners will work together to discover one novel multi-specific antibody drug candidate in each area. Boehringer Ingelheim receives from Numab an exclusive worldwide license to develop and commercialize the resulting candidates in exchange for upfront and milestone payments, as well as tiered royalties on net sales of all products resulting from the alliance.

With today’s announcement, Numab has been able to secure seven ongoing relationships with leading pharmaceutical companies including 3SBio / Sunshine Guojian, Boehringer Ingelheim, Eisai Co., Ltd., CStone Pharmaceuticals, Ono Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., and Tillotts Pharma AG.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/numab



CONTACTS :

Media Contacts
Boehringer Ingelheim:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: 49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Numab Therapeutics:
David Urech
Chief Executive Officer
d.urech@numab.com

For media
MacDougall
Sara Michelmore or Caroline Rufo, PhD.
+1 781-235-3060
numab@macbiocom.com

More Press Releases

Moody’s Analytics Repeats IFRS 9 Wins at Risk Technology Awards

First Eagle to Open Its First German Office in More Than 80 Years; New Hire Louanges Will Direct International Wholesale Business From Munich

Hengli Petrochemical Announces Start-up of its 5th PTA Line Utilising INVISTA’s P8 PTA Technology

Dole Unveils Integrated Strategy Against Banana Disease

Spykke Innovations Partners with tracesafe, to Launch Unique COVID Safety Wristbands in India

Freedom for Our Girls: Breaking Menstrual Barriers

Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

Craft Silicon and PayU Announce Strategic Association to Advance Digital Loan Repayment Solutions for Lending Institutions

With World’s 1st AI and ML Powered Annual-Recurring-Subscription-Model, Frinza Is All Set to Disrupt the Global Gifting Industry

Crossbeats Brings You Work from Home’s Best Bud in Its Beast of a New True Wireless Earphones

Preferred Equity Offering of Lead Real Estate via a Digital Securities Issuance, Brought to Market by GRIP, Securitize and Rialto

Andersen Global Continues West African Expansion with Addition of Tax and Legal Firm in Benin

New One-Stop Resource Center Gives Developers a Robust Array of Tools to Easily Manage, Monitor and Integrate Limelight Services

India Angel Fund invests in Mental Wellness Startup IPHM Services, round led by Monaliesa Sarkar, Jyoti Tiwari, Koel Dutta, Sabana Khatoon, Dr. Vikaas Grover and Rahul Narvekar

CoinEx $50M Ecosystem Development Fund Points First Investment as OneSwap

Wipro Selected as Strategic Partner by Metro Bank to Drive IT Transformation

Velodyne Lidar Sensors Power Emesent’s Hovermap to Fly Beyond the Visual Line of Sight

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trialin adults with and without diabetes

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

NWFI Says Everyone is Looking at India as an Alternative to China and Allowing Exports Will Boost the Domestic Industry

UL Issues First Safety Mark for Hyperbaric Chambers in India

Abbott and 1mg Bring Continuous Glucose Monitoring Solutions Closer to Indian Homes

Face Mask Killing Covid-19, Tested by US-Based ISO Certified Laboratory, Developed and Launched by an Indian Start-up

Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

Philips Introduces Revolutionary Haircare High-Tech Devices and DIY Female Grooming Products

Taobao Introduces Maker Rating System to Champion Young Entrepreneurs, Originality

Sustainable Mica Policy and Vision Prepared by Responsible Mica Initiative with Jharkhand Government and Civil Society Support

MOGAS Wins Multimillion Dollar Bid to Supply Valves for Southeast Asian Refinery

Bank of Baroda’s Credit Card Arm Readies for Digital Transformation with Implementation of Fiserv Technology

Aspect Announces General Availability of Aspect Unified IP 7.4 SP1, the Premier Enterprise Contact Center Solution for High Volume Customer Outreach

Recipe for Growth: Balancing Health, Indulgence and Taste Key to Drive Biscuit and Cookie Growth in India

Automation Industry Leader, Armstrong Along With Indian Rocket Scientists Launched UWe Safe for Contactless 3D Sanitization

WorldRemit Wishing All Those Celebrating a Blessed Eid al Adha

DNSC Introduces the “Typhoon” C20590 MX, the World’s Lowest Cost 100 ppm Full-Color All-In-One MICR Inkjet System

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
'Conspirators behind Mujib killing, Hasi...
Lord Krishna to celebrate his 1st virtua...
Naidu sets 48-hr deadline for Jagan to w...
Odisha to promote cage culture fisheries...
Indian Army organises free veterinary ca...
Kerala revises norms for containment zon...
More...    
 
 Top Stories
Yediyurappa doing well, clinically ... 
Assam situation limps towards norma... 
Aayush Sharma pens a birthday note ... 
BSE's Q1 consolidated net profit at... 
Jiten Lalwani: This year has been o... 
Manipur CM innaugurates 300-bedded ... 
'Conspirators behind Mujib killing,... 
Ayushmann Khurrana champions women'...